Oral nalbuphine in idiopathic pulmonary fibrosis-associated cough: The CORAL randomized clinical trial

This randomized, double-blind, placebo-controlled, Phase 2b trial examined whether extended-release nalbuphine decreased cough in 165 patients with IPF-associated cough. The primary outcome was the relative change from baseline in 24-hour cough frequency (coughs/hour), which was measured using the Vitalograph VitaloJAK cough monitor.